Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Stomach Neoplasms 6Esophageal Neoplasms 4Gastrointestinal Neoplasms 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Adenocarcinoma 2Solid Tumor 1Rectal Neoplasms 1Pathologic Complete Response 1Neoplasms, Unknown Primary 1Nasopharyngeal Carcinoma 1Locally Advanced Gastric Adenocarcinoma 1Hand-Foot Syndrome 1Colorectal Neoplasms 1Colonic Neoplasms 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Cisplatin 104Radiotherapy, Intensity-Modulated 59Gemcitabine 53toripalimab 35Fluorouracil 30Docetaxel 30Capecitabine 28Radiotherapy 23Drug Therapy 20camrelizumab 19nimotuzumab 16nedaplatin 12Chemoradiotherapy 12sintilimab 11apatinib 11Induction Chemotherapy 11Immune Checkpoint Inhibitors 11spartalizumab 10endostar protein 8Paclitaxel 8Cetuximab 8tislelizumab 7pembrolizumab 7Endostatins 7Bevacizumab 7anlotinib 6Radiation 6Endoscopy 6fludarabine 5S 1 (combination) 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Nasopharyngeal Carcinoma × tegafur-gimeracil-oteracil × Clear all
NCT03904225 2021-06-23

Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis

Zhejiang Cancer Hospital

Phase 2 Unknown
220 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡